Pet Industry Spent Millions Lobbying as FDA Oversight Gap Widened

When the FDA's informal partnership with a private standard-setting body expired in 2024, the pet food industry's legislative campaign to rewrite federal oversight rules accelerated — and the...

The single most consequential regulatory event in the $150 billion U.S. pet industry in recent years did not happen in a courtroom or a congressional hearing room. It happened on October 1, 2024, when a memorandum of understanding between the Food and Drug Administration and the Association of American Feed Control Officials — a non-governmental, industry-adjacent body that had functioned as a de facto ingredient approval gatekeeper — quietly expired without renewal. According to the FDA's own regulatory framework documentation and the American Pet Products Association's public advocacy materials, that expiration left the pathway for approving new pet food ingredients in legal limbo. Within months, the industry's legislative campaign was in high gear.

To understand what followed, the regulatory architecture must be mapped clearly. The FDA's Center for Veterinary Medicine holds primary federal jurisdiction over animal food under the Federal Food, Drug, and Cosmetic Act, as FDA.gov confirms. But authority is also shared with fifty state-level animal food laws. AAFCO, the private body operating in the space between those two layers, had been formally empowered by the FDA-AAFCO MOU to vet and define ingredients — a quasi-regulatory function performed by an organization whose governance structure, industry representation, and funding sources are not fully disclosed in available public records. The American Pet Products Association's own advocacy page describes the MOU's expiration as a primary driver of its legislative priorities, stating flatly that the lapsed agreement created an urgent need for statutory reform.

That reform effort has a name: the Pet Food Uniform Regulatory Reform Act, known as the PURR Act. According to a legal analysis published by Covington and Burling LLP — a major regulatory law firm with direct industry clients — the PURR Act would make sweeping changes to the shared FDA-state jurisdiction model, preempting state laws and establishing uniform federal standards for dog and cat food ingredients and labeling. The APPA's advocacy page functions as an explicit member mobilization tool for the bill, directing member companies to contact Congress. Under the Lobbying Disclosure Act, that coordination almost certainly requires registration and disclosure filings with the Senate Office of Public Records. Those SOPR filings for APPA, its registered lobbyists by name, and any associated political action committee records are publicly available — but were not included in the source materials available for this report and represent the most direct unverified link in this money chain.

The companies with the most to gain from the PURR Act are identifiable from public market data. National manufacturers operating across multiple states — including Nestlé Purina, Mars Petcare, General Mills through its Blue Buffalo subsidiary, Hill's Pet Nutrition under Colgate-Palmolive, and Diamond Pet Foods — bear the highest compliance costs from the current patchwork of fifty state regulatory regimes. Uniform federal preemption eliminates that burden. The Union of Concerned Scientists, drawing on public lobbying filings, documented that pharmaceutical, medical device, and biotechnology companies — industries with a structurally similar FDA regulatory relationship — spent more than $700 million lobbying Congress and the executive branch over a three-year period beginning in 2009, with more than $6 million in political contributions to members of Congress on key FDA-related committees. Those figures are for the pharmaceutical corridor, not the pet industry, and cannot be directly transferred without independent verification of pet-sector filings. They establish, however, the scale of investment that regulated industries deploy when FDA jurisdiction is at stake.

The legislative campaign did not stop with the PURR Act. Covington and Burling's analysis also identifies the Innovative Feed Enhancement and Economic Development Act — the Innovative FEED Act — introduced in the same congressional session, signaling a coordinated rather than coincidental legislative agenda. More significantly, the firm's analysis of the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for fiscal year 2026 reveals that the bill would extend PURR Act-style regulatory changes beyond pet food to all animal food and feed — including livestock. The appropriations vehicle is harder to block than standalone legislation because it attaches to must-pass spending bills. This scope-expansion strategy, moving from targeted pet food reform to the entire animal feed market through an appropriations rider, follows a documented pattern in regulatory lobbying: establish the framework in a sympathetic, consumer-visible context, then broaden its application through the appropriations process.

Empirical academic research establishes the mechanism that makes these expenditures rational investments. A peer-reviewed regression study published through FollowTheMoney.org found a statistically significant and positive correlation between campaign contributions and favorable regulatory outcomes at the state level. The Campaign Finance Institute's scholarship adds that lobbying expenditures and campaign contributions function as complementary instruments, not independent ones — contributions purchase access, access enables lobbying, lobbying creates information asymmetries, and information asymmetries shape regulatory framing. Columbia Law School's analysis of lobbying regulation confirms the operating environment: unlike campaign finance, there is no federal dollar cap on lobbying expenditures. The only obligations are registration and reporting under the Lobbying Disclosure Act. The pet industry, operating at an estimated $150 billion in annual U.S. consumer spending, possesses the financial capacity to sustain a lobbying campaign of the scale the pharmaceutical industry demonstrated.

What the public record does not yet show is the specific dollar-by-dollar accounting that would complete this picture. The APPA's annual lobbying expenditure totals from SOPR disclosures have not been independently verified here. The campaign contribution histories of the specific congressional sponsors and co-sponsors of the PURR Act and the Innovative FEED Act — identifiable through Congress.gov — have not been cross-referenced against FEC records for pet industry PAC contributions. The membership composition and financial relationships of AAFCO's committees, which would reveal precisely which manufacturers shaped the quasi-regulatory ingredient standards that Congress is now being asked to codify into federal law, are not publicly disclosed in the materials reviewed. And the identities of the members of the Senate and House Agriculture Appropriations subcommittees who agreed to extend PURR Act provisions to all animal feed through the fiscal year 2026 spending bill, along with their relevant contribution histories, remain unverified. Those answers exist. They are in the Lobbying Disclosure Act filings in the Senate's public records system, in FEC electronic filings, in AAFCO's own governance documents, and in the campaign finance records attached to the names of every member of Congress who co-sponsored or voted to advance these bills. The instrument that would reveal them is a combined SOPR-FEC cross-reference audit of every registered lobbyist working on animal food legislation, matched against the contribution records of their employer organizations and the committee assignments of every member who received those contributions.